Global Anorexiants Market, By Indication (ADHD, Dravet Syndrome, Lennox-Gastaut Syndrome, Obesity, Weight Loss, Others), Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Route of Administration (Oral, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Anorexiants are appetite suppressing medications that work on the brain. They stimulate the hypothalamus and limbic parts of the brain, which control satiety. Obesity can be treated with anorexiants. According to a World Health Organization report, around 650 million people and 41 million children under the age of five were obese globally in 2017. Some of the anorexiants medications used to treat obesity are lorcaserinER, naltrexone/bupropion ER, orlistat, liraglutide, lorcaserin, and phentermine/topiramate ER. As many drugs have been licensed by the FDA for the treatment of obesity, the anorexiants market is expected to rise in the next years.
Data Bridge Market Research analyses that the anorexiants market was valued at USD 0.82 billion in 2021 and is expected to reach USD 1.22 billion by 2029, registering a CAGR of 5.12% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (ADHD, Dravet Syndrome, Lennox-Gastaut Syndrome, Obesity, Weight Loss, Others), Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Route of Administration (Oral, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Aurobindo Pharma (India), Cipla Inc. (U.S.), Lannett (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Novo Nordisk A/S (Denmark), Currax Pharmaceuticals LLC (U.S.), Eisai Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Merck & Co., Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Anorexiants, often known as appetite suppressants, are a type of medication used to treat obesity. This medicine reduces food consumption by acting on the brain to inhibit appetite. Obesity is a long-term condition in which an individual's extra body fat builds up to the point where it threatens his or her health. When people consume more calories than they expend over time, this occurs. Anorexiants are CNS stimulants that reduce appetite and are available as immediate and extended-release tablets. These are prescription medications that should be used in conjunction with a low-calorie diet and regular exercise.
Anorexiants Market Dynamics
Drivers
- Increasing prevalence of obesity
The increasing prevalence of obesity across the globe will fuel industry growth. Obesity is a condition in which a person's body fat levels have accumulated to the point where they are causing health problems. When people consume more calories than they expend over time, this occurs. Obesity raises the risk of chronic diseases such breast cancer, colon cancer, type 2 diabetes, endometrial cancer, cardiovascular disease, and musculoskeletal issues. Obesity afflicted 650 million people and 340 million children and adolescents worldwide in 2016, according to the World Health Organization. This condition can be avoided by changing one's lifestyle. When a person's body mass index (BMI) exceeds 30, that individual is called obese. Inactivity, genetics, family lifestyle, bad nutrition, drugs, age, and pregnancy can all contribute to obesity.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of anorexiants market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, surging geriatric population and rise in the number of government initiatives to spread awareness will result in the expansion of anorexiants market. Along with this, sedentary lifestyle of people and increasing level of disposable income will enhance the growth rate of the market. Increasing availability of branded drugs and limited physical inactivity are the factors due to which market is anticipated to grow rapidly during the forecast period of 2022-2029.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the anorexiants market’s growth.
Moreover, the market's growth is fueled by rising technological advancement and emerging new markets. These factors will provide beneficial opportunities for the anorexiants market growth.
Restraints/Challenges
On the other hand, high cost of drug development and distribution will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the anorexiants market. Additionally, lack of awareness among people and side effects linked with the anorexiants such as diarrhea, tachycardia, headache, myalgia, insomnia, nausea, vomiting and others will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This anorexiants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anorexiants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Anorexiants market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Anorexiants Market
Obese persons have faced difficulties as a result of the COVID-19 shutdown. During this time, the lifestyle was drastically altered: nutrition, activity, and sleep habits, home office, child care, and social isolation. All of these changes could have contributed to tension and anxiety. It has previously been shown that high levels of perceived stress are linked to a predilection for sweet and fatty foods. Binge eating disorder, which is characterized by compulsive overeating or ingesting abnormal amounts of food while feeling unable to stop and a loss of control, has become more common in this situation. Patients with binge eating problems may have been particularly sensitive to the effects of lockdown, necessitating immediate medical attention. Hence, all these factors lead to the high demand of anorexiants market during pandemic period.
Global Anorexiants Market Scope
The anorexiants market is segmented on the basis of indication, drugs class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Catecholamines Anorexiants
- Serotonin Anorexiants
Indication
- ADHD
- Dravet Syndrome
- Lennox-Gastaut Syndrome
- Obesity
- Weight Loss
- Others
Route of Administration
- Oral
- Subcutaneous
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Anorexiants Market Regional Analysis/Insights
The anorexiants market is analysed and market size insights and trends are provided by country, indication, drugs class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the anorexiants market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the anorexiants market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of obesity and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.
Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to surging level of disposable income in this region. Also, development of healthcare infrastructure and rising number of generic drug manufacturer will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Anorexiants Market Share Analysis
The anorexiants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anorexiants market.
Some of the major players operating in the anorexiants market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Aurobindo Pharma (India)
- Cipla Inc. (U.S.)
- Lannett (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Novo Nordisk A/S (Denmark)
- Currax Pharmaceuticals LLC (U.S.)
- Eisai Co., Ltd. (Japan)
- Takeda Pharmaceutical Company Limited (Japan)
SKU-